Management Team

George B. Schwartz – CEO/President

Mr. Schwartz has served as CEO of DermTech International since mid-2004 and on the company’s Board of Directors since 2000. He previously served as CEO of NDA Partners, LLC, a drug development consulting firm. Prior to that, Mr. Schwartz was a director at SunPharm Corporation, a biotechnology company focused on the development of cancer therapeutics in partnership with Parke-Davis. The company was later sold to GelTex Pharmaceuticals, now part of Genzyme Corporation. Mr. Schwartz was also Senior Vice President at Drexel Burnham Lambert and a partner in the Airlie Group, LP, a venture capital and investment firm whose general partner was controlled by Bass Brothers Enterprises. In 1998, Mr. Schwartz co-led the leveraged buyout of Aircraft Service International Group, Inc., and served as its Chairman until its profitable sale in 2001. Mr. Schwartz received an MBA from the Amos Tuck School at Dartmouth College and his Bachelor of Arts degree from Vanderbilt University.

Sherman Chang, PhD - Director, Molecular Biology

Dr. Chang joined DermTech in June 2006. He received his PhD in Molecular Biology from the University of Pittsburgh and his MS in Biochemistry and BS in Pharmacy from National Taiwan University, Taipei. Following completion of his PhD, he received postdoctoral training in cancer biology in the Department of Regulatory Biology at the Salk Institute. His second postdoctoral training was in cancer biology at the University of California, San Diego, where he was the recipient of an NIH-funded research fellowship. Dr. Chang has more than eight years experience in the microarray field as well as extensive experience in assay development and technology improvement. Prior to joining DermTech, Dr. Chang was Staff Scientist II at Diversa in San Diego, where he worked on enzyme-based product development using microarray-based genomic tools. Prior to Diversa, Dr. Chang held a position as Staff Scientist at Torrey Mesa Research Institute, a subsidiary of Syngenta, where he developed a high throughput method for expression profiling, a method for microarray-based SNP detection and managed collaborative microarray projects for Syngenta.

Jennifer Larson – Director, Business Development

Ms. Larson joined DermTech in 2007. She previously was managing partner of Labfive, a biotechnology consultancy specializing in investor relations. Early in her career she was in the marketing department at Bristol Myers-Squibb, focusing on women’s health care products and analgesics. She then joined Chiron Corporation as part of a three-person communications team responsible for all corporate, media and investor relations. Ms. Larson then became vice president of the Health Care Practice at Porter Novelli in London leading accounts for clients including GlaxoSmithKline, Pfizer, Boston Scientific and the World Cancer Research Fund. From 1996-1998 she worked at Ciba (later, Novartis) in Basle where she led the media relations activities for the merger with Sandoz. Ms. Larson received her BA from UC Berkeley and did graduate studies in molecular biology at UC Berkeley and University of Sydney, Australia.